Hibah Khaja

Olverembatinib improved event-free survival over best available therapy in patients with TKI-resistant chronic phase CML in a phase 2 trial.

Pembrolizumab has demonstrated significant efficacy in patients with advanced neuroendocrine tumors, according to researchers.

Researchers have estimated that failed oncology trials cost about $50 billion to $60 billion each year.